AdCLD-CoV19

AdCLD-CoV19 is a vaccine candidate for the prevention of COVID-19, a disease caused by the SARS-CoV-2 virus. It is developed by the pharmaceutical company Adimmune Corporation based in Taiwan.

Development and Testing

AdCLD-CoV19 is an adenovirus vector vaccine. It uses a harmless virus to deliver a piece of the SARS-CoV-2 virus's genetic material into cells in the body. This triggers an immune response, which can help protect against future infection.

The vaccine is currently in clinical trials to determine its safety and efficacy. The trials are being conducted in accordance with international Good Clinical Practice (GCP) standards and the Declaration of Helsinki.

Efficacy

The efficacy of AdCLD-CoV19 is currently being evaluated in clinical trials. Preliminary results have shown promising signs of the vaccine's ability to stimulate an immune response against SARS-CoV-2.

Safety

The safety profile of AdCLD-CoV19 is also under investigation in ongoing clinical trials. All adverse events are being closely monitored and reported to the relevant health authorities.

Distribution and Administration

Upon approval, the distribution and administration of AdCLD-CoV19 will be coordinated by health authorities in accordance with national vaccination strategies. The vaccine is expected to be administered via intramuscular injection.

See Also

• COVID-19 vaccine
• COVID-19 pandemic
• Adenovirus vaccine
• Clinical trial

References

<references />

This article is a stub related to pharmacology. You can help WikiMD by expanding it!